Deduction under section 35(2AB) for research and development: approval timing not decisive; deduction allowed subject to recomputation

Interpretation of deduction under section 35(2AB) focused on whether pre approval R&D expenditure is allowable. The court held that obtainment timing of prescribed authority approval is not determinative provided the expenditure was incurred for the designated in house research purpose and the facility is ultimately approved; therefore the Assessing Officer's restriction of deduction to post approval periods was set aside and the matter remitted for recomputation. The court relied on legislative intent to incentivise in house R&D, distinguished precedents on timing facts, and required the assessing officer to verify factual approval and recalculate the weighted deduction accordingly.

---

---

Issues:
1. Interpretation of deduction under section 35(2AB) of the Income Tax Act.
2. Application of precedents in determining the allowability of deduction.
3. Relevance of approval date for claiming deduction on research and development expenditure.

Analysis:
1. The judgment dealt with the interpretation of deduction under section 35(2AB) of the Income Tax Act. The appellant, a company engaged in manufacturing automobile parts, claimed a deduction under this section for expenses related to setting up Research and Development facilities. The Assessing Officer disallowed the deduction for the period before the approval date, leading to appeals and subsequent legal proceedings.

2. The appellant relied on the decision in the case of Claris Lifesciences Ltd. to support their claim for deduction. However, the CIT(Appeals) and the Tribunal distinguished this precedent based on the timing of approval and application. The Tribunal remanded the case to the Assessing Officer for further verification, highlighting contradictory facts regarding the approval date.

3. The judgment discussed the relevance of the approval date for claiming deduction on research and development expenditure. The Tribunal's decision was challenged based on precedents from the Claris Lifesciences Ltd. case and a judgment from the Delhi High Court. The Court emphasized that the approval date is not determinative for claiming the deduction, as long as the expenditure was incurred for the specified purpose and the facility was approved by the prescribed authority.

4. The Court analyzed the legislative intent behind section 35(2AB) to encourage in-house research and development facilities by granting weighted deductions. It emphasized that the approval of the facility by the prescribed authority is a crucial condition for claiming the deduction. The judgment clarified that the period during which approval is granted is not relevant as long as the approval exists and the expenditure was incurred for the designated purpose.

5. Ultimately, the Court allowed the appeal, setting aside the Assessing Officer's decision to restrict the deduction for expenditure incurred before a specific date. The Court emphasized that the purpose of the deduction is to promote research and development activities, acknowledging the uncertainties and time delays involved in obtaining approvals. The Assessing Officer was directed to recompute the deduction for the relevant assessment year based on the Court's interpretation of the law.

6. In conclusion, the judgment provides a detailed analysis of the interpretation of deduction under section 35(2AB) of the Income Tax Act, the application of precedents in determining the allowability of deductions, and the significance of approval dates for claiming deductions on research and development expenditure.

---